JP2022512573A5 - - Google Patents
Info
- Publication number
- JP2022512573A5 JP2022512573A5 JP2021517796A JP2021517796A JP2022512573A5 JP 2022512573 A5 JP2022512573 A5 JP 2022512573A5 JP 2021517796 A JP2021517796 A JP 2021517796A JP 2021517796 A JP2021517796 A JP 2021517796A JP 2022512573 A5 JP2022512573 A5 JP 2022512573A5
- Authority
- JP
- Japan
- Prior art keywords
- dtt
- bont
- seq
- lysc
- shows
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023185401A JP7819168B2 (ja) | 2018-09-28 | 2023-10-30 | 外因性活性化ループを含むクロストリジウム神経毒 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1815817.0 | 2018-09-28 | ||
| GBGB1815817.0A GB201815817D0 (en) | 2018-09-28 | 2018-09-28 | Clostridial neurotoxins comprising and exogenous activation loop |
| PCT/GB2019/052732 WO2020065336A1 (en) | 2018-09-28 | 2019-09-27 | Clostridial neurotoxins comprising an exogenous activation loop |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023185401A Division JP7819168B2 (ja) | 2018-09-28 | 2023-10-30 | 外因性活性化ループを含むクロストリジウム神経毒 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022512573A JP2022512573A (ja) | 2022-02-07 |
| JP2022512573A5 true JP2022512573A5 (https=) | 2022-09-06 |
| JPWO2020065336A5 JPWO2020065336A5 (https=) | 2022-09-06 |
| JP7511549B2 JP7511549B2 (ja) | 2024-07-05 |
Family
ID=64108972
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517796A Active JP7511549B2 (ja) | 2018-09-28 | 2019-09-27 | 外因性活性化ループを含むクロストリジウム神経毒 |
| JP2023185401A Active JP7819168B2 (ja) | 2018-09-28 | 2023-10-30 | 外因性活性化ループを含むクロストリジウム神経毒 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023185401A Active JP7819168B2 (ja) | 2018-09-28 | 2023-10-30 | 外因性活性化ループを含むクロストリジウム神経毒 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12589139B2 (https=) |
| EP (1) | EP3856232A1 (https=) |
| JP (2) | JP7511549B2 (https=) |
| KR (1) | KR20210068476A (https=) |
| CN (1) | CN113164565A (https=) |
| AU (1) | AU2019348732C1 (https=) |
| BR (1) | BR112021005017A2 (https=) |
| CA (1) | CA3111962A1 (https=) |
| EA (1) | EA202190889A1 (https=) |
| GB (1) | GB201815817D0 (https=) |
| IL (1) | IL281814A (https=) |
| MX (1) | MX2021003261A (https=) |
| SG (1) | SG11202102323TA (https=) |
| TW (2) | TW202517790A (https=) |
| UA (1) | UA130362C2 (https=) |
| WO (1) | WO2020065336A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3481852B1 (en) * | 2016-07-08 | 2022-12-07 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| GB201815817D0 (en) * | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
| GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
| GB202104294D0 (en) | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
| WO2022208091A1 (en) | 2021-03-30 | 2022-10-06 | Ipsen Biopharm Limited | Treatment of pain & inflammatory disorders |
| JP7659653B2 (ja) | 2021-03-30 | 2025-04-09 | イプセン バイオファーム リミテッド | 疼痛及び炎症性障害の処置 |
| CN115785237B (zh) * | 2022-09-01 | 2023-06-16 | 上海蓝晶生物科技有限公司 | 一种重组肉毒杆菌毒素及其制备方法 |
| GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
| GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
| GB202214229D0 (en) * | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
| CN116813727B (zh) * | 2023-06-08 | 2025-06-06 | 苏州德进生物制药有限公司 | 一种a型肉毒毒素的制备方法及其应用 |
| GB202320108D0 (en) | 2023-12-28 | 2024-02-14 | Ipsen Biopharm Ltd | Biosensor |
| CN118126143B (zh) * | 2024-03-14 | 2025-06-24 | 河北平朴生物科技合伙企业(有限合伙) | 一种a型肉毒毒素的突变体及其应用 |
| GB202404021D0 (en) | 2024-03-20 | 2024-05-01 | Ipsen Biopharm Ltd | Cell-based neurotoxin assay |
| CN119859174B (zh) * | 2025-01-13 | 2026-03-20 | 乐普健糖药业(重庆)有限公司 | 重组肉毒毒素及其制备方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| AU3658093A (en) | 1992-02-10 | 1993-09-03 | Seragen, Inc. | Desensitization to specific allergens |
| GB9305735D0 (en) | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| DK1084146T3 (da) | 1998-05-13 | 2003-02-03 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Hybridprotein til inhibering af degranuleringen af mastocyter og anvendelse deraf |
| ES2205849T3 (es) | 1998-07-22 | 2004-05-01 | Osprey Pharmaceuticals Limited | Conjugados para tratar alteraciones inflamatorias y asociadas con daños tisulares. |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| WO2000039310A1 (en) * | 1998-12-29 | 2000-07-06 | The University Of Georgia Research Foundation, Inc. | Rubredoxin fusion proteins, protein expression system and methods |
| US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
| US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
| HK1046020B (en) | 1999-08-25 | 2007-05-11 | Allergan, Inc. | Activatable recombinant neurotoxins |
| GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| US6903187B1 (en) | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
| US7273722B2 (en) | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
| US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
| US7514088B2 (en) | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| PL1830872T3 (pl) | 2004-12-01 | 2011-09-30 | Sec Dep For Health | Białka fuzyjne |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| ES2369558T3 (es) | 2005-09-19 | 2011-12-01 | Allergan, Inc. | Toxinas clostridiales y toxinas clostridiales activables. |
| EP1931379B1 (en) * | 2005-10-07 | 2013-05-29 | Health Protection Agency | Proteins with improved solubility and methods for producing and using same |
| EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| AU2007272515B2 (en) | 2006-07-11 | 2013-09-26 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| JP2009543558A (ja) | 2006-07-11 | 2009-12-10 | アラーガン、インコーポレイテッド | 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素 |
| JP5799397B2 (ja) * | 2008-06-12 | 2015-10-28 | イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ | 癌の抑制 |
| GB0815264D0 (en) | 2008-08-21 | 2008-09-24 | Syntaxin Ltd | Non-cytotoxic proteins |
| KR20110106346A (ko) | 2008-12-10 | 2011-09-28 | 알러간, 인코포레이티드 | 클로스트리디움 독소 약제학적 조성물 |
| GB0903006D0 (en) | 2009-02-23 | 2009-04-08 | Syntaxin Ltd | Modified non-cytotoxic proteases |
| CA2758274C (en) | 2009-04-14 | 2018-04-10 | Mcw Research Foundation, Inc. | Engineered botulinum neurotoxin |
| CZ2010374A3 (cs) * | 2010-05-13 | 2011-06-29 | Zentiva, K.S. | Rekombinantní produkce teriparatidu v bakteriích Escherichia coli |
| US8853360B2 (en) | 2010-06-23 | 2014-10-07 | Wisconsin Alumni Research Foundation | Engineered botulinum neurotoxin C1 with selective substrate specificity |
| GB201108108D0 (en) | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
| WO2013091895A1 (en) | 2011-12-23 | 2013-06-27 | Merz Pharma Gmbh & Co. Kgaa | Novel method for the manufacturing of di-chain proteins for use in humans |
| US20140056870A1 (en) | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
| WO2014079495A1 (en) | 2012-11-21 | 2014-05-30 | Syntaxin Limited | Methods for the manufacture of proteolytically processed polypeptides |
| GB201407525D0 (en) | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| CN107108703B (zh) * | 2015-01-09 | 2022-09-23 | 益普生生物创新有限公司 | 阳离子神经毒素 |
| GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| US11242515B2 (en) | 2016-05-16 | 2022-02-08 | President And Fellows Of Harvard College | Method for purification and activation of botulinum neurotoxin |
| EP3481852B1 (en) * | 2016-07-08 | 2022-12-07 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| WO2019152380A1 (en) | 2018-01-30 | 2019-08-08 | Children's Medical Center Corporation | Production of botulinum neurotoxins using bacillus systems |
| GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
-
2018
- 2018-09-28 GB GBGB1815817.0A patent/GB201815817D0/en not_active Ceased
-
2019
- 2019-09-27 UA UAA202102226A patent/UA130362C2/uk unknown
- 2019-09-27 SG SG11202102323TA patent/SG11202102323TA/en unknown
- 2019-09-27 EP EP19782680.3A patent/EP3856232A1/en active Pending
- 2019-09-27 BR BR112021005017-5A patent/BR112021005017A2/pt unknown
- 2019-09-27 WO PCT/GB2019/052732 patent/WO2020065336A1/en not_active Ceased
- 2019-09-27 KR KR1020217012010A patent/KR20210068476A/ko not_active Ceased
- 2019-09-27 AU AU2019348732A patent/AU2019348732C1/en active Active
- 2019-09-27 TW TW113126928A patent/TW202517790A/zh unknown
- 2019-09-27 CN CN201980078275.8A patent/CN113164565A/zh active Pending
- 2019-09-27 JP JP2021517796A patent/JP7511549B2/ja active Active
- 2019-09-27 MX MX2021003261A patent/MX2021003261A/es unknown
- 2019-09-27 TW TW108135053A patent/TWI869353B/zh active
- 2019-09-27 US US17/278,724 patent/US12589139B2/en active Active
- 2019-09-27 EA EA202190889A patent/EA202190889A1/ru unknown
- 2019-09-27 CA CA3111962A patent/CA3111962A1/en active Pending
-
2021
- 2021-03-25 IL IL281814A patent/IL281814A/en unknown
-
2023
- 2023-10-30 JP JP2023185401A patent/JP7819168B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512573A5 (https=) | ||
| JPWO2020065336A5 (https=) | ||
| Eddleston et al. | Molecular profile of reactive astrocytes—implications for their role in neurologic disease | |
| TW200635945A (en) | Antibodies against IL-13 receptor alpha 1 and uses thereof | |
| WO2007047829A3 (en) | Novel heterodimeric proteins and uses thereof | |
| ES2689746T3 (es) | Anticuerpos monoclonales contra la claudina-18 para el tratamiento de cáncer | |
| NO20061026L (no) | Nye insulinderivater | |
| WO2005068494A3 (en) | Chimera botulinum toxin type e | |
| AR077931A2 (es) | Anticuerpos contra la interleuquina-13 humana y usos de los mismos | |
| WO2002074964A3 (fr) | Polypeptides derives des arn polymerases, et leurs utilisations | |
| EP1549767A4 (en) | MODULATION OF EXPRESSION OF FORKHEAD BOX O1A | |
| EP2567981A3 (en) | Anti-glycoprotein VI SCFV fragment for treatment of thrombosis | |
| Peters et al. | Further studies on Pseudomonas aeruginosa LasA: analysis of specificity | |
| TW200516143A (en) | 5'-and 3'-capped aptamers and uses thereof | |
| WO2004070046A8 (ja) | 糖鎖アスパラギン誘導体の製造方法 | |
| WO2003035679A3 (en) | Molecules | |
| UA87128C2 (ru) | ИММУНОГЛОБУЛИН АНТИ-EрCAM И СПОСОБ ЕГО ВВЕДЕНИЯ ДЛЯ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ | |
| Fusi et al. | Ribonucleases from the extreme thermophilic archaebacterium S. solfataricus | |
| JP2006063085A (ja) | クロストリディウム属細菌の神経毒の作用を延長させる組成物および方法 | |
| WO2003092611A3 (en) | Methods of inducing formation of functional and organized lymphatic vessels | |
| DE19951196A1 (de) | Massgeschneiderte Peptidsynthetasen und ihre Verwendung | |
| EP1118669A9 (en) | Production of camelid antibodies in plants | |
| WO2009044294A3 (en) | Means and methods for the treatment of cataract and presbyopia | |
| WO2001025267A3 (en) | Improved ricin-like toxins for treatment of cancer | |
| CA2441187A1 (en) | Acetyllysine-recognizing monoclonal antibody and process for producing the same |